Skip to main content

NextGen Discovery Series – September 24, 2024

“From Lab to Life: Transforming care for Ultra-Rare Genetic Disorders”

Speaker: Yael Weiss, MD, PhD, Chief Executive Officer, Mahzi Therapeutics

Date: September 24, 2024, noon-1 p.m.

Location: Roy Blunt NextGen Precision Health Building, Atkins Family Seminar Room

*Zoom option available 

 Register Here

 

About the Speaker

Yael Weiss portraitDr. Weiss Is currently CEO of Mahzi Therapeutics, a company focused on the development of therapies for ultra-rare genetic neurodevelopmental disorders. Mahzi works closely with patient foundations to support their journey towards drug development and bring programs into Mahzi once pre-clinical proof of concept is established.

She completed her MD at Hadassah Medical School at the Hebrew University in Jerusalem and her PhD at the Weizmann Institute of Science in Rehovot, Israel. She has over 20 years of industry experience in medical/clinical and business development roles at Genzyme, Merck and Ultragenyx. Dr. Weiss is a member of ASGCT and AES translational committee, N=1 collaborative and is a 2022 Termeer Fellow. Board member/advisor to Everlum and ADNP, FOXG1 KCNT1 and Team Telomere foundations.

 

About the Discovery Series

The NextGen Precision Health Discovery Series provides learning opportunities for UM System faculty and staff across disciplines, the statewide community and our other partners to learn about the scope of precision health research and identify potential collaborative opportunities. The series consists of monthly lectures geared toward a broad multidisciplinary audience so all can participate and appreciate the spectrum of precision health efforts. 

For questions about this event or any others in the Discovery Series, please reach out to Veronica Lemme at lemmev@health.missouri.edu.